AIM Biopharmaceuticals

AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases. The company's lead product is Ampligen (rintatolimod), a double-stranded RNA molecule that acts as a selective Toll-like receptor 3 (TLR3) agonist. Ampligen is currently being evaluated in various clinical trials for oncology indications, including pancreatic and ovarian cancers, as well as for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post-Acute Sequelae of SARS-CoV-2 (Long COVID). AIM ImmunoTech aims to leverage its proprietary dsRNA technology to modulate the immune system and provide new treatment options for patients with significant unmet medical needs.